Ultra-low Dose Bevacizumab Plus Temozolomide for Recurrent High-grade Gliomas

Clinical trial NCT02416999 · UNKNOWN

Trial details

NCT number: NCT02416999
Sponsor: Hebei Yanda Hospital
Status: UNKNOWN
Phase: Not Applicable
Study type: INTERVENTIONAL

Recurrent High-grade Glioma

Start date: 2015-05-01
Primary completion: 2018-05-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.